Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome

Movement Disorders

Volumn 11, Issue 6, 1996, Pages 726-728

  Jauss, M ^a   Krack, P ^a   Franz, M ^a   Klett, R ^a   Bauer, R ^a   Gallhofer, B ^a   Dorndorf, W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

123I IBZM SPECT; Catatonia; Neuroleptic malignant syndrome; Parkinsonism

Indexed keywords

AMANTADINE; BENZAMIDE; CREATINE KINASE; DANTROLENE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; TRACER;

ADULT; AKINESIA; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; EXTRAPYRAMIDAL SYMPTOM; FEVER; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REMISSION; RIGOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TACHYCARDIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BENPERIDOL; BENZAMIDES; DOPAMINE ANTAGONISTS; FRONTAL LOBE; HALOPERIDOL; HUMANS; IODINE RADIOISOTOPES; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029846018     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110621     Document Type: Article

References (17)

1. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145.
2. Schröder J, Linge C, Wähner A. Zur Differentialdiagnostik der malignen Hyperthermie, der febrilen Katatonie und des neuroleptisch malignen Syndroms: ein kasuistischer Vergleich. Fortschr Neurol Psychiatr 1988;56:97-101.
3. Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of NMS. Gen Pharmacol 1990;21:367-386.
4. 2 dopamine receptor imaging agent. J Nucl Med 1990; 30:88-92.
5. 123I-Iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556-561.
6. Webster DD. Critical analysis of the disability in Parkinsons disease. Mod Treat 1968;5:257-282.
7. Costa DC, Verhoeff NPLG, Cullum ID, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide 123-I in humans. Eur J Nucl Med 1990;16:813-816.
8. 2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994;90(4):266-268.
9. 2 receptors with 123-I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707.
10. Tatsch K, Schwarz J, Kerner M, Oertel WH. Idiopathisches Parkinson Syndrom: 123-I-IBZM SPECT vor und unter Therapie. Nucl Med 1993;32:A13.
11. Jann MW, Eveshetsky L, Saklad SR. Clinical pharmakokinetics of the depot antipsychotics. Clin Pharmacokinet 1985;10:315-333.
12. Wistedt B, Jørgensen A, Wiles D. A depot neuroleptic withdrawal study. Psychopharmacology 1982;78:301-304.
13. Giltlin MJ, Midha KK, Fogelson D, Nuechterlein K. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 1988;8:53-56.
14. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76.
15. Harasko-van der Meer C, Wöber C, Wenger S, Podreka I, Brücke T. Dopaminrezeptorblockade durch verschiedene Kalziumantagonisten erklärt extrapyramidale Nebenwirkungen [Abstract]. Annual Meeting of the Austrian Parkinson Society, Innsbruck, 14-15 May 1993.
16. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48:977-981.
17. Sczesni B, Becker H, Schröder J, et al. Diagnostische und therapeutische Effekte des neuroleptischen maligenen Syndroms anhand von 12 Fällen. Wien Klin Wochenschr 1991;103/1:21-26.